Article
Regenerative repair after endoluminal injury in mice with specific antagonism of protease activated receptors on CD34+ vascular progenitors.
Department of Immunology, Imperial College London, Hammersmith Hospital, London, UK.
Blood (impact factor:
9.9).
05/2008;
111(8):4155-64.
DOI:10.1182/blood-2007-10-120295
pp.4155-64
Source: PubMed
-
Citations (0)
- Cited In (1)
-
Article: Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments.
[show abstract] [hide abstract]
ABSTRACT: Atrial fibrillation (AF) is the most common cardiac rhythm disorder and a major risk factor for ischemic stroke. Antithrombotic therapy using aspirin or vitamin K antagonists (VKA) is currently prescribed for prevention for ischemic stroke in patients with AF. A narrow therapeutic range and the need of regular monitoring of its anticoagulatory effect impair effectiveness and safety of VKA, causing a need for alternative anticoagulant drugs. Recently developed anticoagulants include direct thrombin antagonists such as dabigatran or factor Xa inhibitors such as rivaroxaban, apixaban, betrixaban, and edoxaban. Currently, data from a phase III clinical trial are available for dabigatran only, which show the direct thrombin antagonist to be at least noninferior in efficacy to VKA for the prevention of stroke and systemic embolism in patients with AF. This review focuses on current advances in the development of directly acting oral anticoagulant drugs and their potential to replace the VKA class of drugs in patients with AF.Journal of the American College of Cardiology 12/2010; 56(25):2067-76. · 14.16 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
activated endothelial cells
continued recruitment
direct actions
florid neointimal lesions
inhibited apoptosis
injured vessel wall
intimal hyperplasia
minority population
mixed-phenotype VPs
neointimal cells
neointimal smooth muscle cells
outgrowth
PAR antagonists inhibited IH
protease-activated receptors
Thrombin
thrombin influences VP phenotype
vascular injury
VP coexpressing markers
VPs
wire-induced carotid artery injury